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Abstract
Background: Autism spectrum disorders (ASD) represent a group of neurodevelopmental disorders characterized
by a core set of social-communicative and behavioral impairments. Gamma-aminobutyric acid (GABA) is the major
inhibitory neurotransmitter in the brain, acting primarily via the GABA receptors (GABR). Multiple lines of evidence,
including altered GABA and GABA receptor expression in autistic patients, indicate that the GABAergic system may
be involved in the etiology of autism.
Methods: As copy number variations (CNVs), particularly rare and de novo CNVs, have now been implicated in ASD
risk, we examined the GABA receptors and genes in related pathways for structural variation that may be associated
with autism. We further extended our candidate gene set to include 19 genes and regions that had either been
directly implicated in the autism literature or were directly related (via function or ancestry) to these primary
candidates. For the high resolution CNV screen we employed custom-designed 244 k comparative genomic
hybridization (CGH) arrays. Collectively, our probes spanned a total of 11 Mb of GABA-related and additional
candidate regions with a density of approximately one probe every 200 nucleotides, allowing a theoretical resolution
for detection of CNVs of approximately 1 kb or greater on average. One hundred and sixty-eight autism cases and
149 control individuals were screened for structural variants. Prioritized CNV events were confirmed using
quantitative PCR, and confirmed loci were evaluated on an additional set of 170 cases and 170 control individuals
that were not included in the original discovery set. Loci that remained interesting were subsequently screened via
quantitative PCR on an additional set of 755 cases and 1,809 unaffected family members.
Results: Results include rare deletions in autistic individuals at JAKMIP1, NRXN1, Neuroligin4Y, OXTR, and ABAT.
Common insertion/deletion polymorphisms were detected at several loci, including GABBR2 and NRXN3. Overall,
statistically significant enrichment in affected vs. unaffected individuals was observed for NRXN1 deletions.
Conclusions: These results provide additional support for the role of rare structural variation in ASD.
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Background
Autism spectrum disorders (ASD) represent a group of
neurodevelopmental disorders characterized by a core
set of social-communicative and behavioral impairments.
There is abundant evidence for a strong genetic contri-
bution to ASD, with concordance rates among MZ
twins ranging from 60% to 90% [1]. It is now evident
that the underlying genetic architecture of autism is
highly complex, with numerous genomic loci contribut-
ing to overall risk. Efforts to identify specific risk loci
have met with some success, and variants in several
genes and genomic regions having been implicated to
date. These loci include SHANK3, CNTNAP2, NLGN4X,
pCDH10, 16p11.2, NRXNa1, SYNGAP, SEMA5A,a n d
AVPR1A, among others [2-6]. Evidence for the role of
common variation in ASD risk was reported within the
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important advances, phenotypic and genetic heterogene-
i t yh a v em a d ei tc h a l l e n g i n gt ou n r a v e lt h eu n d e r l y i n g
causes of ASD, and a substantial component of this dis-
order’s genetic etiology remains to be discovered.
Copy number variation and ASD
A number of studies have implicated copy number varia-
tions (CNVs) in ASD [8-15]. In addition to specific struc-
tural mutations, global enrichment in rare and/or de
novo CNVs has been reported within affected vs.u n a f -
fected individuals (for example [5,7-15]). To date, studies
examining copy number variation in ASD have relied
heavily on array technologies that were originally
designed for the purpose of conducting SNP-based gen-
ome-wide association studies (GWAS). This is primarily
due to the fact these data already exist (that is they were
obtained for genotyping purposes). These GWAS arrays
typically place a limit on the resolution at which CNVs
can be reliably detected at 10 to 50 kb or larger (contin-
gent upon the array and analysis parameters), although
smaller events can be detected in certain circumstances.
The use of custom designed comparative genomic hybri-
dization (CGH) arrays, combined with a targeted, candi-
date-gene oriented strategy, can extend the ability to
reliably detect variation below 10 kb. As it is evident that
structural DNA variation with potential relevance to
pathological phenotypes can and does exist at sub-10 kb
scales (for example [16]), we sought to examine a subset
of autism candidate regions at high resolution. The
GABA receptor family of genes and genes within biologi-
cal pathways associated with GABA are attractive candi-
dates for autism and ASD. GABA is the primary
inhibitory neurotransmitter in the human brain, and it is
known to assume both excitatory and inhibitory roles
during early development stages [17,18]. Previously our
group has reported evidence of both linkage and associa-
tion with ASD at the GABA receptor genes in the 15q11-
13 region [19,20]. In addition, differential expression of
GABA receptors has been observed in ASD cases
[21-23], and rare coding variants in GABRB3 have been
found that segregate with ASD [24]. In light of the above
evidence, we chose to examine 24 GABA receptors and
19 additional GABA-related genes for evidence of sub-5
kb structural variation that might contribute to the aut-
ism/ASD risk. We further extended our candidate gene
set to include an additional 19 genes and regions that
had been previously implicated in autism (Table 1).
These loci were either recognized ASD candidates or
directly related to ASD candidates through biological
function or sequence homology. Targeted genes include
members of the Neurexin and Neuroligin gene families,
the CDH9/CHD10 region on chromosome 5p, the
1 6 p 1 1 . 2r e g i o n s ,C N T N A P 2 ,O X T ,O X T R ,M E C P 2 ,a n d
Table 1 Targeted genes and regions (hg18 coordinates)
Gene/locus Chr Start Stop
GABRD chr1 1940703 1952050
ALDH9A1 chr1 163898073 163934524
GAD2 chr10 26545600 26633493
GABARAPL1 chr12 10256756 10266991
GABR CLUSTER®GABR-A/B/G chr15 24339787 25451729
ABAT chr16 8675928 8785933
GABARAPL2 chr16 74157750 74169280
ZDHHC7 chr16 83565573 83602642
GABARAP chr17 7084462 7086477
LOC649186 chr19 61520464 61521066
DBI chr2 119840974 119846592
GAD1 chr2 171381446 171425905
SLC32A1 chr20 36786519 36791429
GABRR3 chr3 99188217 99236521
ZDHHC3 chr3 44941665 44992618
JAKMIP1 chr4 6106385 6253183
GABRG1 chr4 45732544 45820839
GABRA2 chr4 45946463 46087178
GABRA4 chr4 46615674 46690337
GABRB1 chr4 46728336 47123202
SLC6A7 chr5 149549713 149570828
GABRB2 chr5 160648014 160907708
GABRA6 chr5 161045548 161061690
GABRA1 chr5 161206983 161258992
GABRG2 chr5 161427295 161515106
GABRP chr5 170143343 170173628
ALDH5A1 chr6 24603176 24645414
GABBR1 chr6 29631387 29708839
GABRR1/GABRR2 chr6 89944691 90081673
GABBR2 chr9 100090187 100511300
GABRE chrX 150872252 150893807
GABRA3 chrX 151087186 151370486
GABRQ chrX 151557293 151572481
SV2A chr1 148140546 148159156
SLC12A5 chr20 44091245 44122196
SLC38A3 chr3 50217709 50233408
SLC6A1 chr3 11009456 11055935
SLC6A11 chr3 10832917 10955146
SLC6A12 & SLC6A13 chr12 167240 245958
CHR5 Peak Association Region chr5 24400928 27150205
CD38 chr4 15389029 15459804
OXT chr20 3000266 3001162
OXTR chr3 8767095 8786300
BDNF chr11 27631325 27707500
EN2 chr7 154943585 154950287
MECP2 chrX 152940458 153016323
SHANK3 chr22 49459936 49518504
MBD1 chr18 46045698 46064286
MBD2 chr18 49916985 50016488
MBD3 chr19 1527678 1543652
MBD4 chr3 130632483 130641542
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regions have been previously examined for structural var-
iation in the context of GWAS array analysis, these loci
have not been systematically targeted with custom
designed high resolution aCGH in a population of ASD
and control individuals to survey fine-scale structural
variation.
Methods
Ethical approval
This research was carried out in accordance with the
World Medical Association’s Declaration of Helsinki.
Participants in the study were ascertained under applic-
able IRB protocols of the John P. Hussman Institute for
Human Genetics (HIHG), University of Miami, Miller
School of Medicine, Vanderbilt University Medical Cen-
ter, and University of California, San Francisco (UCSF)
Medical School. Following a description of the study,
informed consent was obtained for each individual or,
where appropriate, their guardian.
Ascertainment and DNA extraction
Individuals were recruited as part of our ongoing family-
based recruitment via support groups, advertisements,
and clinical and educational settings. Written informed
consent was obtained from parents for all minor children
and those who were unable to give consent. In addition,
we obtained assent from all participants of the appropri-
ate developmental and chronological age. Core inclusion
criteria were as follows: (1) between 3 and 21 years of
age, (2) a clinical diagnosis of ASD, (3) an expert clinical
determination of ASD diagnosis using DSM-IV criteria
supported by the Autism Diagnostic Interview (ADI-R)
[25,26], and (4) an IQ equivalent > 35 or developmental
level >18 months as determined by the Vineland Adap-
tive Behavior Scale (VABS) [27]. A best estimate diagnos-
tic determination was based on review by a three-person
panel, including experienced clinical psychologists and a
pediatric medical geneticist. This determination included
ADI-R results. In those instances where an ADI-R was
not available (n = 86; six were parents, 67 were lost to
follow-up, refused to complete the interview, or with-
drew, and 13 are in progress), a best-estimate diagnosis
was assigned by this panel using all available clinical
information including clinician summaries, caregiver
report, and medical records. Following review of case
materials and discussion, panel members reached a con-
sensus. We excluded participants with severe sensory
problems (for example visual impairment or hearing
loss), significant motor impairments (for example failure
to sit by 12 months or walk by 24 months), or identified
metabolic, genetic, or progressive neurological disorders.
Family history and pedigree information was collected in
a standard semi-structured interview from a knowledge-
able informant, frequently the mother. Additional clinical
data were also collected by reviewing available medical
and psychiatric records of affected individuals.
The majority of control participants were recruited by the
HIHG at the University of Miami and included 565 chil-
dren between the ages of 3 and 21 years. Participants with
developmental, behavioral, or neurological conditions were
excluded, as well as those with first-degree relatives with
such disorders. We obtained consent from all participants
or, in the case of minors, their parents. Participants meeting
these criteria provided a saliva sample. A knowledgeable
informant, usually the mother, completed the Social Com-
munication Questionnaire to screen for potential ASDs
[28]. The above controls were supplemented with addi-
tional set of 65 individuals obtained from the UCSF School
of Medicine. Blood samples were obtained from self-
reported Non-white Hispanics, ranging from 15 to 37 years
of age and reporting no history of chronic disease.
For the CNV discovery stage of the project, DNA from
whole blood and/or saliva (Oragene kit) was collected from
173 Caucasian non-Hispanic and Caucasian Hispanic aut-
ism cases and 185 racially matched control individuals
(≤37 years of age) with no known signs of ASD (matched
backgrounds were confirmed with Eigenstrat clustering
[29]). As described below, data from some samples were
excluded from further analysis based on laboratory QC
metrics, resulting in a final sample set of 168 cases and 149
controls. CNV loci that were molecularly confirmed and
trended towards significance were subsequently tested
within a larger sample set of 2,564 individuals, consisting
of 755 affected (728 Caucasian/non-Hispanic, 17 Asian, 7
Hispanics, 3 African-Americans) and 1,809 unaffected indi-
viduals who were family members of the 755 cases.
Table 1 Targeted genes and regions (hg18 coordinates)
(Continued)
NRXN1 chr2 49993980 51150855
NRXN2 chr11 64130222 64247236
NRXN3 chr14 77528262 79502905
FOXP2 chr7 113404235 114320494
CNTNAP2 chr7 145444386 147749019
chr16p11.2 chr16 29478715 30278715
NLGN1 chr3 174785171 175483810
NLGN2 chr17 7252226 7263903
NLGN3 chrX 70278940 70308868
NLGN4-Y chrY 15144026 15464921
NLGN4-X chrX 5818083 6156706
Positive and negative controls (common polymorphisms)
Deletion/duplication chr1 109988334 109993086
Deletion/duplication chr3 99893514 99897268
Deletion chr3 194260213 194265258
Deletion/duplication chr10 132799241 132802636
Duplication chr16 4710525 4715494
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using the Autopure (Gentra) system according to the
manufacturer’s standard protocols. For a subset of six con-
trol individuals for which DNA extracted from both blood
and saliva sources was available, we ran replicate CGH
arrays on both blood and saliva DNA in order to look for
any systematic differences evident between the two
sources. Although batch effects attributable to numerous
experimental factors have been previously noted for CNV
studies, quality metrics and total CNV events called indi-
cated no significant DNA-source effects within this CGH-
based study. Specifically, Nexus 4.1 (Biodiscovery) noise
metrics and CNV copy call numbers showed no systematic
differences between blood and saliva groups (Additional
file 1: Table S1).
Target gene selection
In addition to the set of GABA-related gene targets form-
ing the primary focus of this study, a set of 19 additional
ASD candidates were selected based on several criteria,
including a recently completed GWAS [7]. The list
included both a set of genes previously implicated in the
ASD literature, as well as genes known to interact biologi-
cally and/or exhibit significant homology to those genes.
As not all putative and/or established ASD loci could be
accommodated on the array, the final prioritized list was
arrived at by consensus among study collaborators.
CGH array design
We designed a custom 244 k Agilent comparative geno-
mic hybridization (CGH) array targeting our regions of
interest. Array hybridization probes were chosen using
Agilent earray software https://earray.chem.agilent.com/
earray/, with a preference for catalogue probes, where
available. Probe design was based on coordinates from
the hg18 build of the human reference sequence. Collec-
tively, our probes spanned a total of approximately 11
Mb with an average probe density of one unique probe
every 200 nucleotides. Given that most standard CNV
calling approaches require four to five consecutive sig-
nificant probes to identify an aberrant region, our cover-
age theoretically allows for the detection (on average) of
CNVs 800 bp or larger. The GABA family of receptors
poses particular challenges for hybridization-based copy
number assays. Due to the level of sequence homology
resulting from the ancestral relationships among GABA
genes, increased background probe noise within con-
served regions was anticipated. In an effort to mitigate
the influence of assay noise on the CNV calling algo-
rithm, we employed triplication of all internal experi-
mental probes as well as running technical array
replicates of a subset of 40 individuals to aid in identify-
ing and excluding problematic regions.
Array processing
Genomic DNA was fragmented, enzymatically labeled,
hybridized to arrays, and washed according to the manu-
facturer’s (Agilent) standard protocols. Briefly, 0.75 μgo f
extracted DNA from a single hybridization reference indi-
vidual (sample NA10851, available from the US National
Institute of General Medical Sciences (NIGMS) Human
Genetic Cell Repository) was labeled with Cy3 dye (follow-
ing recommendation of [30]). An equal amount of
extracted DNA from experimental samples was enzymati-
cally labeled with Cy5 dye. Labeled samples for each
experimental individual was combined with labeled refer-
ence DNA, hybridized to the CGH array for 40 h at 65°C,
and washed to remove non-hybridized fragments prior to
imaging.
Imaging and analysis
All arrays from this study we r ei m a g e du s i n gas i n g l e
Molecular Devices GenePix 4000B microarray scanner,
processed with Agilent Feature Extraction 9.5 and ana-
lyzed with Nexus (Biosdiscovery) software version 4.1.
Preliminary analysis was conducted using Rank Segmen-
tation (an extension of the circular binary segmentation
algorithm [31] as implemented in Nexus 4.1. Final results
presented in this manuscript are based on the Nexus
Rank segmentation algorithm with the gain/loss LogR
threshold set to 0.25, maximum inter-probe distance at
25 kb, and the (default) minimum of five probes required
per called CNV event.
Quality control
As indicated above, each probe was replicated three times
(each at a randomly distributed location) on the CGH
array and fluorescent signal intensities were averaged prior
to subsequent analysis. For detection of common sample
handling errors, markers on the X chromosome were
examined to ensure observed sample sex was consistent
with the original sample manifest. In addition, sex chromo-
some markers, as a proxy for true-positive controls, a set of
five highly polymorphic CNV locations reported in the
Database of Genomic Variation http://projects.tcag.ca/var-
iation/ were used to evaluate the ability of our array design
(and associated processing technique) to detect structural
DNA variation at scales of 5 kb and below (Table 1 bot-
tom). Because the selected loci harbored reported minor
allele frequencies of 15% and above, each of the minor
structural alleles was expected to be observed, with high
probability, one or more times within our sample of 317
individuals. All five of the targeted CNVs were readily
detected within our sample population. Although it was
observed as variant in our sample set, one of the five tar-
gets chosen from the database, hg18 locus chr16:4710525-
4715494, was found upon further examination to harbor
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hybridization results questionable. We therefore do not
recommend its use as a positive control locus in future
experiments.
To identify potential outlier samples (with respect to
sample quality) total CNV calls per individual were rank
sorted. A clear demarcation point was observed at
approximately 60 total CNV calls per individual, with a
relatively small number of samples exhibiting significantly
higher numbers of CNV calls. We suspected that the
excess number of calls associated with these arrays was
attributable to poor sample quality or processing issues; as
evidence of this, the Nexus 4.1 quality metric (a measure
of probe-to-probe variation across contiguous probes)
among these individuals was elevated compared to that of
the non-excluded set. Collectively, our quality criteria
resulted in a subset of 41 samples being excluded from all
subsequent analysis.
Statistical analysis of CNV calls
Initial CNV calls output from Nexus 4.1 rank segmenta-
tion algorithm were converted to compatible format for
loading into PLINK [32]. For the purpose of analysis,
PLINK provides the option of handling heterogeneous
CNV calls at the same genomic locus by treating each
unique CNV start and stop coordinate as separate mar-
kers. Any copy number gain (or loss) that overlaps the
p o s i t i o no fam a r k e ra s s u m e sav a l u e( 0 ,1 ,2 ,3 ,o r4 -
plus copies) for the marker. After initial processing in
PLINK to produce a .ped file with CNV markers, logisti-
cal regression analysis was conducted via R scripting.
Results of logistic regression analysis are provided in
Additional file 2: Table S2. Regression results corre-
sponding to -LOG10 (P value) ≥ 3 were evaluated as
candidates for additional analysis. For analysis of the lar-
ger family-based dataset, the GENMOD procedure (SAS
vers8.1) was run on the dataset and a generalized esti-
mating equation (GEE) was employed to account for the
relationships between the parents and siblings (unaf-
fected) and cases. GEE allows for specification of a cor-
relation matrix of the between-subject relatedness of
participants belonging to the same pedigree [33] and is
commonly used in the context of genetic epidemiology
studies to produce robust variance estimates that other-
wise would likely be too small/conservative in the pre-
sence of relatedness between observations [34]. For each
of the candidate genes evaluated by GEE at the valida-
tion stage of the study, Bonferroni correction was used
to correct for the number CNV positions examined
within the candidate. Global CNV burden was assessed
using the mperm option in PLINK to perform a global
permutation test (10,000 permutations) on segment
number, total kilobase difference, and average kilobase
difference.
Molecular confirmation of CNV calls
Prioritized loci were validated by real-time quantitative
PCR using TaqMan chemistry (a full list of target loca-
tions are provided in Additional file 3: Table S3). Assays
were performed in quadruplicate, as recommended by
the manufacturer (Applied Biosystems {Life Technolo-
gies, Carlsbad, CA}), reactions were run on the ABI-
7900HT real-time PCR system and analyzed using
CopyCaller software v.1.0 (Life Technologies, Carlsbad,
CA). Regions were chosen for validation based on sev-
eral criteria, including their potential for biological rele-
vance and logistic regression scores (Additional file 2:
Table S2). CNVs spanning known exons were given the
highest priority, followed by those including regions of
evolutionary conservation, as evidenced by interspecies
sequence homology (per UCSC Genome Browser, build
36.1, March 2006, conservation tracks). Some predicted
copy number variable regions that exhibited statistically
significant scores were nevertheless excluded from
further analysis because data from technical replicates
indicated poor replicability for calls at these regions.
Examination of these loci indicated that they tended to
exhibit extreme GC content, repetitive element content,
or extensive homology to other areas of the genome
likely due to common ancestry and subsequent evolu-
tionary conservation (data not shown). In addition to
the above criteria, CNV regions were excluded from fol-
low-up if they exibited 75% or greater overlap with
known copy number variable regions reported in DGV
http://projects.tcag.ca/variation/; however, exceptions
were made in cases where the variants encompassed
exons within candidate genes and instances where
gained or loss alleles were discordant in case/controls.
All loci meeting these criteria subjected to TaqMan
CNV assays (Applied Biosystems) for further interroga-
tion in additional cases and controls.
Results and discussion
A total of 24 GABA receptors, 19 GABA-associated
coding genes, and 19 additional autism candidates were
targeted for aCGH assessment (Table 1). After exclusion
of outlier samples, a total of 168 case and 149 control
individuals were examined by CGH arrays in the initial
discovery set. In all, 6,143 CNV events calls were identi-
fied across our tested population, representing 1,223
potentially unique variations. The overall number of
CNV events did not exhibit significant differences
between ASD affected and unaffected individuals,
although both the average and total kilobases impacted
did show statistical significance (perm P < 0.001; 10,000
permutations; one-sided), consistent with previous
reports indicating pathogenic CNVs tend to be larger in
size and over-represented in affected individuals (for
example [35]). The full list of CNV calls from the Nexus
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file 4: Table S4. The logistic regression analysis of case
and control allele frequencies were used, in conjunction
with additional biological annotation criteria, to priori-
t i z eas u b s e to fr e g i o n sf o rc o n f i r m a t i o nv i aas e c o n d
molecular platform, TaqMan copy number quantitative
PCR assays (Applied Biosystems). In addition to the
ASD candidate loci prioritized for follow-up, five control
genomic regions, representing known polymorphic loca-
tions with minor allele frequencies >10%, were also tar-
geted with TaqMan assays to test the sensitivity of our
laboratory technique. The 29 targeted regions and five
control loci targeted for follow-up are detailed in Addi-
tional file 3: Table S3, along with confirmation results.
A diagram of the work flow for discovery and validation
is provided in Additional file 5: Figure S1. The sample
set used for molecular confirmation and additional
population screening was comprised of the individuals
in which the CNVs were initially observed (for confir-
mation), along with an additional 170 Caucasian cases
and 170 unaffected ethnically-matched controls that
were not present in the original discovery set (Table 2).
A subset of independently confirmed loci that remained
interesting was run on a larger set of 755 case and 1,809
unaffected family members. GEE analysis results for
these data, accounting for relationships between indivi-
duals, are provided in Table 3.
Targeted CNV call events were confirmed with quanti-
t a t i v eP C Ra t1 3o f2 9l o c i ,4 5 % .T h i ss u g g e s t sam i n i -
mum false-positive rate (at the locus level) of 55%
(addressed below).
Phenotypic evaluation
Medical records were examined for a subset of indivi-
duals harboring rare CNV events at loci of interest
(ABAT, NRXN1, JAKMIP1, GABBR2, NLGN2, OXTR).
We examined salient phenotypic and medical history
characteristics for these individuals to look for common-
alities among carriers of CNVs at particular loci. Charac-
teristics examined included developmental abnormalities
in speech and motor development, learning disabilities,
and evidence of dysmorphologies. Additional co-morbid-
ities (for example irritable bowel syndrome, asthma) and
neuropsychiatric features were also noted. No obvious
correspondence between aberrant CNV state and specific
phenotypic traits was observed. A summary of available
phenotypic and medical characteristics for the individuals
examined is provided in Additional file 6: Table S5.
In addition to these rare variants, common structural
polymorphisms were observed and validated at multiple
loci, including NRXN3, CNTNAP2, GABBR2, SLC38A3,
and NLGN2. Of these more frequent events, only the
GABBR2 locus approached nominal significance (GEE;
P = 0.029; OR = 1.16; 95% CI: 0.7-1.93) in our larger
validation set, but the result was not significant at a =
0.025 after correction for multiple testing (Table 3).
The role of structural variation, particularly rare and de
novo CNVs, in autism has been established in a number
of previous studies. Here we examined a set of autism
candidate loci using high-resolution aCGH analysis. Our
principal objective was to detect structural variants at
these loci that may have been potentially missed by other
screening platforms, such as SNP-based arrays. Among
the limitations impacting our study was the presence of a
high false-positive rate (in excess of 50%) in our initial
aCGH discovery set. The most likely explanation for this
elevated false-positive rate is that the majority of genes in
our study, including both GABA and non-GABA-related
targets (for example MBD1-MBD4), belong to families of
homologous genes which can lead to aberrant probe
hybridization. As the majority of loci in our study
belonged to homology groups, we could not formally test
for this effect. In addition, the modest overall sample
numbers used in this study limited our ability to accu-
rately estimate population allele frequencies for rarer
events. Even with these complicating factors, several pro-
mising events were detected and independently con-
firmed by quantitative PCR. Rare structural variations
were detected at ABAT, NLGN4-Y, NRXN1, and JAK-
MIP1 (Table 2). Most notable among these results, statis-
tically significant enrichment of deletions (GEE; P =
0.0215; OR = 2.75; 95% CI: 1.161-6.5; a = 0.025) in
affected vs. unaffected individuals was observed at
NRXN1 within our larger family-based validation set
with after correction for multiple testing (Table 3).
We observed and confirmed an approximate 4 kb dele-
tion in a female autistic indvidual within the JAKMIP1
gene that removes two exons. JAKMIP1, a member of a
family of microtubule interacting proteins, is known to
interact with GABBR1 protein [36] and knockdown of its
expression via siRNA results in increased GABBR2
expression, suggesting a possible role for JAKMIP1 in
GABBR2 regulation. Misregulation of JAKMIP1 has also
been observed in lymphoblastoid cell lines from autistic
individuals [37]. We note, however, that no significant
enrichment for the deletion was observed in our larger
validation set. More detailed characterization of these
deletions in the affected and unaffected individual is war-
ranted before further inference can be made, as the pre-
cise boundaries of the deletion events may be different in
case and control individuals.
A large (approximately 70 kb) deletion encompassing
two exons of the NRXN1 genes was detected in an autistic
male (Figure 1). NRXN1 is a neuronal adhesion molecule
that has been implicated in a number of neurological disor-
ders, including autism (for example [38-41]. Suggestive
SNP association results at the NRXN1 locus were reported
in a large collaborative study, but genome-wide significance
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reported for rare structural events [42]. The removal of
this exonic region within an autistic male in our dataset,
along with the detection of significant enrichment of
NRXN1 deletions in cases vs. unaffected individuals in this
study, provides further evidence for NRXN1 as an ASD
risk locus. Furthermore, the location of our CNV, along
with the placement of previously reported NRXN1 events
(Figure 1), suggest that disruptions of the alpha form of
NRXN1. The beta form of NRXN1, which is transcribed
from a secondary downstream promoter, is less frequently
observed to be disrupted by CNV in ASD cases. Combined
with the aforementioned genetic association results, our
data suggests that both rare and common variants may be
contributing to ASD risk at this genomic location.
A deletion of the entire Neuroligin 4Y gene within an
autistic male was also observed and confirmed. In the lar-
ger dataset, the deletion was observed in the original indi-
vidual’su n a f f e c t e df a t h e ra sw e l la sw i t h i na nu n a f f e c t e d
male sibling. Two additional unaffected carriers (unre-
lated) were also observed in the larger dataset. Interest-
ingly, however, we observed two duplication events within
the larger validation set, both of which were present in
unrelated ASD individuals. Neuroligin 4Y, which resides
on the non-recombining portion of the Y chromosome in
modern humans was, in the evolutionary past, allelic with
Neuroligin 4X (NLGN4X) gene. Several studies have pre-
viously implicated NLGN4X in autism (for example
[50-52]). Nucleotide mutations in NLGN4Y have been
reported in an autistic male and his father, who possessed
learning disabilities [53]. While there is currently no data
regarding the functional status and possible role of
NLGN4Y, EST evidence from the NCBI database suggests
that NLGN4Y retains a molecularly active promoter and is
expressed in the brain. A recent report demonstrated a
potential role for some pseudogenes in regulating the
expression of their parent or source genes by providing
decoy targets for miRNAs [54]. It is possible that, through
this or some other mechanism, NLGN4Y is involved in
regulating the expression of the NLGN4X locus in males.
Our finding of copy number aberrations of this gene in
autistic individuals suggests that the locus warrants further
investigation.
We observed a deletion at the ABAT gene locus within
multiple ASD individuals, one in our discovery dataset and
a second case ASD case in the validation set. Further
examination of the locus within the larger, family based set
revealed 7 of 755 affected individuals carrying the deletion
Table 2 Taqman case/control confirmation set data
Indel region (hg18 coordinates) LOCUS Estimated size (bp) Case (gain) Control (gain) Case (loss) Control(loss)
Previously described rare events
chr3:8,749,197-8,795,876 OXTR
a 46679 1 0 1 1
Novel rare events
chr16:8,666,148-8,704,012 ABAT 37864 0 0 1 0
chr2:50,948,094-51,013,968 NRXN1-probeA 65874 0 0 1 1
NRXN1-probeB 0 0 1 0
chr3:50,207,690-50,243,268 SLC38A3 35578 0 0 5 8
chr4:6,158,503-6,162,618 JAKMIP1 4115 0 0 1 1
chrY:15,135,574-15,474,858 NLGN4Y 339284 0 0 1 0
aOXTR loci was previously reported in [33] but was examined here within a novel group of individuals.
Table 3 GEE results from family-based validation dataset (n = 2,564, 755 affected and 1,809 unaffected individuals)
Parameter Z PR P value OR Lower limit Upper limit
GABBR2_1
a
Deletion 0.3100 0.7582 1.14 0.500 2.587
Duplication -2.1800 0.0292 0.72 0.542 0.968
Event -1.9800 0.0476 0.76 0.579 0.997
NRXN1_1
a
Deletion 2.3000 0.0215 2.75 1.161 6.508
Duplication 1.1500 0.2515 3.24 0.435 24.085
Event 2.5300 0.0114 2.81 1.262 6.258
NRXN1_2
a
Deletion 2.1400 0.0320 2.33 1.075 5.059
Duplication -0.9700 0.3309 0.34 0.040 2.963
Event 0.8500 0.3959 1.40 0.644 3.040
aContains deletion or duplication significant at P < 0.05. Only loci demonstrating statistical significance are shown here.
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Page 7 of 11and five (of 1,809) unaffected individuals (unrelated to the
seven affected individuals). Although we observed a trend
of enrichment in affected vs. unaffected individuals in our
dataset, statistical significance was not met at a = 0.05.
The observed trend, however, suggests that ABAT locus,
and the GABA system as a whole, warrant further scrutiny
for their potential role in ASD risk. ABAT is involved in
the catabolism of GABA, has previously been implicated in
autism by genetic association, although replication of the
association was not observed in the small validation dataset
(n = 91 autism trios) [55]. In the one deleted individual
from our dataset for which CGH array data was available
at the locus, the ABAT deletion removes exon 1 of the
gene (Additional file 7: Figure S2). We note that the nearby
A2BP1 and GRIN2A loci, which have also been implicated
in autism [55], were not included in our deleted region
(Additional file 8: Figure S3).
We also observed a previously reported deletion in the
OXTR receptor in a single male ASD individual [56]. A
smaller duplication region in OXTR was also detected
in a separate ASD case.
In addition to the rare copy number events described
above, we also observed and confirmed common copy
number polymorphisms at SLC38A3, GABBR2, NRXN3,
SHANK3, and NLGN2 (Table 2). Among these, only
duplication events in GABBR2 achieved nominal statisti-
cal significance at a = 0.05, but this result failed to hold
up after multiple correction for multiple testing.
Furthermore, the relatively high level of background
noise of assays targeting this locus makes us approach
the GABBR2 finding with caution. Additional examina-
tion of the locus through alternative platforms (for
example long-read high throughput sequence technolo-
gies) will be necessary before further conclusions can be
drawn.
Conclusions
These data further indicate the importance of structural
variation in ASD risk and provide additional evidence
that rare variants at multiple genomic loci are poten-
tially contributing to this common neurodevelopmental
disorder. In particular, we report statistically significant
Glessner et al 2009 
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Figure 1 A deletion of approximately 70 kb encompassing two exons (3,4) from the NRXN1 gene (alpha-1-isoform). Previously reported
NRXN1 CNV events in ASD cases are shown mapped below [38-40,42-49]. A subset of NRXN1 structural variants reported in individuals with
mild to severe intellectual disability is also depicted [49]. Solid lines indicate deletions (majority) and dashed lines indicate duplication events.
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Page 8 of 11enrichment of rare exonic deletions in NRXN1 in autis-
tic vs. non-autistic individuals. The detection and confir-
mation of structural variants below the 10-50 kb
typically afforded by SNP-based GWAS arrays indicate
that aCGH remains an important complementary
method for CNV detection.
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